Reuters logo
BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease
October 20, 2017 / 12:21 PM / a month ago

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

Oct 20 (Reuters) - Albireo Pharma Inc

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

* Albireo Pharma Inc - ‍A4250 reduced serum bile acids and improved pruritus in most patients, exhibited a favorable overall tolerability profile​

* Albireo Pharma Inc - ‍albireo to conduct phase 3 study of a4250​ in children with progressive familial intrahepatic cholestasis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below